Sangamo Therapeutics Inc

Sangamo Therapeutics, headquartered in Brisbane, California, is a clinical-stage genomic medicine company that develops therapies using a proprietary zinc finger nuclease (ZFN) platform to precisely edit, regulate or add genes. The firm pursues both in vivo genome editing and ex vivo cell-engineering approaches, along with zinc finger–based gene regulation, to address rare monogenic disorders and neurological and metabolic diseases; its pipeline includes clinical-stage candidates and earlier-stage programs for indications such as hemophilia and lysosomal storage disorders. Sangamo advances programs through internal development and partnerships with larger biopharma companies, deriving revenue from collaborations, milestone payments and potential future commercialization.